JBCHEPHARM - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.0
| Stock Code | JBCHEPHARM | Market Cap | 34,104 Cr. | Current Price | 2,123 ₹ | High / Low | 2,177 ₹ |
| Stock P/E | 46.9 | Book Value | 238 ₹ | Dividend Yield | 0.73 % | ROCE | 25.9 % |
| ROE | 20.2 % | Face Value | 1.00 ₹ | DMA 50 | 1,982 ₹ | DMA 200 | 1,827 ₹ |
| Chg in FII Hold | -0.76 % | Chg in DII Hold | -0.12 % | PAT Qtr | 179 Cr. | PAT Prev Qtr | 200 Cr. |
| RSI | 64.8 | MACD | 47.2 | Volume | 4,35,699 | Avg Vol 1Wk | 5,47,625 |
| Low price | 1,303 ₹ | High price | 2,177 ₹ | PEG Ratio | 1.97 | Debt to equity | 0.01 |
| 52w Index | 93.9 % | Qtr Profit Var | 14.6 % | EPS | 46.5 ₹ | Industry PE | 27.6 |
📈 Chart & Trend: JBCHEPHARM is trading above both its 50 DMA (₹1,982) and 200 DMA (₹1,827), with the current price at ₹2,123. This indicates strong bullish momentum and trend continuation potential.
📊 RSI: At 64.8, RSI is approaching overbought territory, suggesting strong momentum but caution for short-term traders.
📈 MACD: Positive at 47.2, confirming bullish momentum and trend strength.
📉 Bollinger Bands: Price is near the upper band, reflecting strong buying interest but also risk of short-term pullback.
📊 Volume: Current volume (4.35 Lakh) is slightly below average weekly volume (5.47 Lakh), showing reduced participation but still supportive of stability.
📍 Support & Resistance:
- Strong support: ₹1,982 (50 DMA)
- Immediate resistance: ₹2,177 (recent high)
- Major resistance: ₹2,250+
Optimal entry zone: ₹2,050–₹2,100 (near support).
Exit zone: ₹2,170–₹2,200 (resistance cluster).
🔎 Trend Status: The stock is trending upward with bullish bias. Sustained close above ₹2,177 could trigger further upside momentum.
Positive
- ROCE (25.9%) and ROE (20.2%) indicate strong capital efficiency.
- Low debt-to-equity (0.01) ensures financial stability.
- EPS at ₹46.5 supports earnings visibility.
- Strong 52-week index performance at 93.9% shows robust long-term momentum.
Limitation
- P/E of 46.9 compared to industry PE of 27.6 indicates overvaluation.
- PEG ratio of 1.97 suggests valuation is not cheap relative to growth.
- Volume participation is lower than average, limiting breakout strength.
Company Negative News
- PAT declined to ₹179 Cr from ₹200 Cr, showing earnings pressure.
- FII holding decreased by -0.76% and DII holding by -0.12%, reflecting reduced institutional confidence.
Company Positive News
- Quarterly profit variation of 14.6% indicates growth momentum.
- Dividend yield of 0.73% provides modest income support.
Industry
- Industry PE at 27.6 vs JBCHEPHARM’s PE of 46.9 shows relative premium valuation.
- Pharma sector outlook remains positive with strong demand drivers and defensive characteristics.
Conclusion
⚖️ JBCHEPHARM is trending upward with bullish bias. Short-term traders may consider entry around ₹2,050–₹2,100 with exits near ₹2,170–₹2,200. Long-term investors can accumulate gradually given strong fundamentals, but caution is advised due to high valuation and reduced institutional support.
Would you like me to prepare a pharma basket overlay (JBCHEPHARM vs peers like Sun Pharma, Divi’s Lab, Cipla) so you can benchmark its setup against sector leaders for confirmation signals?